Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins

Julien Favresse, Julie Cadrobbi, Christine Eucher, Marc Elsen, Kim Laffineur, Jean-Michel Dogné, Jonathan Douxfils

Research output: Contribution to journalArticlepeer-review

15 Downloads (Pure)

Abstract

This study assesses the clinical performance of three anti-SARS-CoV-2 assays, namely EUROIMMUN anti-SARS-CoV-2 nucleocapsid (IgG) ELISA, Elecsys anti-SARS-CoV-2 nucleocapsid (total antibodies) assay, and LIAISON anti-SARS-CoV-2 spike proteins S1 and S2 (IgG) assay. One hundred and thirty-seven coronavirus disease 2019 (COVID-19) samples from 96 reverse-transcription polymerase chain reaction confirmed patients were chosen to perform the sensitivity analysis. Non-SARS-CoV-2 sera (n = 141) with a potential cross-reaction to SARS-CoV-2 immunoassays were included in the specificity analysis. None of these tests demonstrated a sufficiently high clinical sensitivity to diagnose acute infection. Fourteen days since symptom onset, we did not find any significant difference between the three techniques in terms of sensitivities. However, Elecsys performed better in terms of specificity. All three anti-SARS-CoV-2 assays had equivalent sensitivities 14 days from symptom onset to diagnose past-COVID-19 infection. We also confirmed that anti-SARS-CoV-2 determination before Day 14 is of less clinical interest.

Original languageEnglish
Pages (from-to)2262-2269
Number of pages8
JournalJournal of medical virology
Volume93
Issue number4
DOIs
Publication statusE-pub ahead of print - 2020

Keywords

  • covid-19
  • SARS-CoV-2
  • serology
  • symptom onset
  • cut-off
  • COVID-19

Fingerprint

Dive into the research topics of 'Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins'. Together they form a unique fingerprint.

Cite this